Haemonetics Corp at Morgan Stanley Healthcare Conference Transcript
Okay. So let's get going. We're getting kind of a late start here. My apologies. My name is David Lewis, medical device analyst from Morgan Stanley. It's my pleasure to have with me this morning Haemonetics Corporation as we progress through the morning, and their CEO, Chris Simon.
Questions & Answers
We're going to jump right into it. And Chris, there is -- I think I may not -- I don't think I've ever see a more rapid transformation of a business for a mid-cap medical device company than we've seen at Haemonetics. Frankly, since you joined, we've seen growth acceleration, really transformative costs. So the question, and we talked about a little bit of this in our CEO call a few months back, but what's next for you in terms of what's the next phase of transformation at Haemonetics?
Yes. Thanks, David. I appreciate the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |